Pfizer Inc - Mar 17, 2023 Form 4/A - Amendment Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
10%+ Owner
Signature
/s/ Susan Grant, Assistant Secretary
Stock symbol
PYXS
Transactions as of
Mar 17, 2023
Transactions value $
$4,999,999
Form type
4/A - Amendment
Date filed
3/23/2023, 04:14 PM
Date Of Original Report
Mar 21, 2023
Previous filing
Dec 29, 2022
Next filing
Mar 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock, $0.001 par value per share Purchase $5M +1.81M +43.75% $2.76 5.95M Mar 17, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were issued under that certain first amendment dated March 16, 2023 to the Amended and Restated License Agreement dated October 14, 2022 between the Reporting Person and the Issuer, pursuant to which the Issuer agreed to issue to the Reporting Person such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of the Issuer's common stock on the business day when the closing price of the Issuer's common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day between March 16, 2023 and a date that is within 180 days following October 6, 2022.
F2 On March 17, 2023, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.76 per share.

Remarks:

The only amendments made to the previously filed Form 4 are to add footnotes (1) and (2) in column (4).